Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03372733
Recruitment Status : Recruiting
First Posted : December 14, 2017
Last Update Posted : January 13, 2020
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

Brief Summary:

Background:

Omega-7 fatty acids are found in the oil extracted from certain fish and nuts like macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies suggest that this oil is good for heart health. Researchers want to find out more about these potential benefits.

Objective:

To study how oil enriched with palmitoleic acid (Omega-7 oil) affects metabolism.

Eligibility:

Healthy adults at least 18 years old with no known history of cardiovascular disease.

Subjects not allergic to fish oil and fish products

Females that are not pregnant and are not planning a pregnancy during the length of the study

Design:

Participants will be screened with questions about their health, medical history, and medicines they take.

Participants will have 4 visits over 24 30 weeks. The visits may include:

  • Blood drawn from a vein in the arm by a needle stick. Sometimes participants will have to fast before the blood draw.
  • Vital signs (blood pressure, heart rate, and temperature) taken
  • Body mass index measured
  • Cardio-Ankle Vascular Index test. The stiffness of the participant s arteries will be measured by reading blood pressure in the arms and legs and monitoring the heart.
  • Optional stool samples
  • Pregnancy test
  • A short review of participants physical activity and diet
  • Appetite and satiety test. Participants will fast the night before, then answer questions about appetite and feeling full. They will get a light breakfast and then a light lunch.
  • A supply of dietary supplements to take between visits. Participants will take 4 gel capsules a day.

Participants will keep a food and exercise journal

Compensation will be provided to subjects that complete the study

Check your eligibility for this study by clicking here: https://www.surveymonkey.com/r/DietaryOmega


Condition or disease Intervention/treatment Phase
Cardiovascular Disease Drug: control olive oil (COO) Drug: palmitoleate-rich oil (PLO) Phase 2

Detailed Description:

Serum cholesterol is transported by lipoproteins, such as VLDL, LDL and HDL, which vary in their relationship to cardiovascular disease risk. LDL, for example, is proatherogenic, whereas HDL is cardio-protective. Palmitoleic acid (cis-C16:1 n-7), an omega-7 fatty acid with 16 carbons in length with a single double bound in the n-7 position, have been shown in mice and human to decrease proatherogenic lipoproteins, such as LDL, and reduce cardiovascular risk factors. This study will test the hypothesis that palmitoleate supplementation in humans will favorably alter the lipoprotein lipid profile in regard to cardiovascular disease risk. We will also assess other parameters related to lipoprotein composition and function, as well as other biomarkers related to coagulation and inflammation, which have previously been shown to be possibly affected by supplementation with omega-7 fatty acid. In addition, previous animal studies have indicated the palmitoleate induced satiety and suppressed bodyweight gain, possibly through enhancement of the release of satiety hormones. In this clinical trial, we, therefore will also examine the effect of concentrated palmitoleate on satiety.

This clinical research project is designed as a pilot, randomized, double-blinded, crossover study that will investigate the effect of concentrated oil enriched with palmitoleate on lipoprotein metabolism and satiety. Subjects will either receive control olive oil enriched in oleic acid, a longer-chain monounsaturated fatty acid (cis-C18:1 n-9), or a concentrate oil supplement produced from pollock fish (rich in palmitoleate) for approximately 8-10 weeks, with a wash out period of 8-10 weeks between the two arms of the study. The study consists of 4 outpatient visits when laboratory or research samples and CAVI tests will be performed. A 7-day food diary, pill count, and red cell membrane fatty acid levels will be monitored to assess compliance. The effect of the supplement on satiety will be assessed at each visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Effect of Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
Actual Study Start Date : July 31, 2018
Estimated Primary Completion Date : July 31, 2020
Estimated Study Completion Date : July 31, 2020

Arm Intervention/treatment
Experimental: Group 1
Subjects randomized to the control olive oil armwill take the equivalant to 3g of control /day in twodivided doses (4 capsules a day) for 8 +/- 2 weeks andcross-over to the palmitoleate-rich oil
Drug: control olive oil (COO)
2 capsules, 2 times a day after meals in a total of 4 capsules a day

Experimental: Group 2
Subjects randomized to the Subjects randomizedto the control olive oil arm will take the equivalant to3g of control /day in two divided doses (4 capsulesa day) for 8 +/- 2 weeks and cross-over to thepalmitoleate-rich oil arm will take the equivalant to3g of control /day in two divided doses (4 capsulesa day) for 8 +/- 2 weeks and cross-over to the contrololive oil
Drug: palmitoleate-rich oil (PLO)
2 capsules, 2 times a day after meals in a total of 4 capsules a day




Primary Outcome Measures :
  1. Changes in the LDL-cholesterol levels [ Time Frame: 24 weeks ]
    The primary outcome measures of this study will be changes in the LDL- cholesterol levels. Secondary outcome measurements will be changes in TC, TG, HDL-C, and other lipids, lipoprotein particle number, HDL functional test (i.e. efflux study) composition and size, changes in appetite and/or satiety. Each subject will serve as their own control.


Secondary Outcome Measures :
  1. Changes in TC, TG, HDL-C, and other lipids, lipoprotein particle number, HDL functional test (i.e. efflux study) composition and size,changes in apetite and/or satiety [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:
  • Male and female participants 18 years of age or above.
  • Subject must be healthy, with no known history of cardiovascular disease.
  • Post-menopausal or women of childbearing potential must be non-lactating and using an effective form of birth control during the course of the study.
  • Subject understands protocol and provides written, informed consent in addition to a willingness to comply with specified follow-up evaluations.
  • Subjects with a BMI greater than or equal to 25 kg/m2 or a triglycerides level greater than or equal to 100 mg/dL (only one of these parameter need to be met)

EXCLUSION CRITERIA:

  • Pregnancy, planned pregnancy (within the study period) or women currently breastfeeding.
  • Subjects with allergy or known hypersensitivity to fish, omega-3-acid ethyl esters, omega-7 ethyl esters, other related drugs, or any component of study drugs
  • Subjects with weight changes greater than 20% over the past 3 months.
  • Subjects planning a significant change in diet or exercise levels.
  • Subjects already consuming more than 2 g per day of MUFA, PUFA or other forms of fatty acid supplement if determined by the inverstigator as having a potential to interfere in the data quality or patient safety.
  • Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.
  • Subjects with any acute and life-threatening condition, such but not limited to as prior sudden cardiac arrest, acute myocardial infarction (last three months), stroke, embolism as per investigator accessment.
  • Subjects taking supplements or medications that affect lipoproteins for at least the past 8 weeks, such as fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins, Niacin or PCSK9 inhibitors.
  • Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for >4 weeks.
  • Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion
  • Anticipated surgery during the study period
  • Liver enzymes (AST or ALT) levels above 3x upper limit of normal
  • Blood donation in the last 2 weeks or planned blood donation during the study
  • Subjects requiring regular transfusions for any reason
  • Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data.
  • Abnormal baseline laboratory values that are considered not clinically significant by the PI will not exclude the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03372733


Contacts
Layout table for location contacts
Contact: OPR Office of Patient Recruitment Not Listed emma.staller@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Marcelo J Amar, M.D. National Heart, Lung, and Blood Institute (NHLBI)

Additional Information:
Layout table for additonal information
Responsible Party: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT03372733    
Other Study ID Numbers: 180019
18-H-0019
First Posted: December 14, 2017    Key Record Dates
Last Update Posted: January 13, 2020
Last Verified: January 3, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
Omega-7
Palmitoleic Acid
Monounsaturated Fatty Acids
Lipoproteins
Satiety
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases